ICML 2019 | Bispecific AFM13 plus pembro for R/R Hodgkin lymphoma
AFM13 is a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. Here Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the trial of AFM13 plus pembrolizumab in patients with relapsed/refractory Hodgkin lymphoma after brentuximab vedotin failure (NCT02665650). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
Get great new content delivered to your inboxSign up